Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

Global Prevalence of Diabetes

Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297

β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011

The mechanism of pancreatic secretion

Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,274

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.

Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 2×

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906

The role of incretins in glucose homeostasis and diabetes treatment

Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793

Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice

Zhang, H., Dong, M., Yuan, S., & Jin, W. (2022) · Biotechnology Letters · doi:10.1007/s10529-022-03288-1 · Cited by 7

Antibacterial and Antiviral Properties of Tetrahydrocurcumin-Based Formulations: An Overview of Their Metabolism in Different Microbiotic Compartments

Atanasova-Pančevska, N., Stojchevski, R., Hadzi‐Petrushev, N., Mitrokhin, V. M., Avtanski, D. B., & Mladenov, M. I. (2022) · Life · doi:10.3390/life12111708 · Cited by 7

Designer GLP1 poly-agonist peptides in the management of diabesity

Statham, L., Pelling, M., Hanson, P., Kyrou, I., Randeva, H. S., & Barber, T. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204976 · Cited by 7

The metabolic actions of neurotensin secreted from the gut

Ratner, C., Hundahl, C., & Holst, B. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000085 · Cited by 7

The Effect of Semaglutide on Gut Microbiota in Chinese Patients with Type 2 Diabetes Poorly Controlled by Metformin

Chen, Y., Shan, Y., Wang, T., Liu, Z., Zhao, Z., & He, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s537001 · Cited by 6

Medicinal plants: A promising source of anti-diabetic agents in sub-Sahara Africa

Aloke, C., Egwu, C. O., Adelusi, O. A., Chinaka, N. C., Kanu, S. C., Ogbodo, P. N., Akumadu, B. O., & Achilonu, I. (2023) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2023-0012 · Cited by 6

Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications

Tudurachi, B.-S., Anghel, L., Tudurachi, A., Sascău, R. A., Zanfirescu, R.-L., & Stătescu, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061314 · Cited by 7

Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective

Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 7

Adropin Is Expressed in Pancreatic Islet Cells and Reduces Glucagon Release in Diabetes Mellitus

Ali, I. I., D’Souza, C. M., Tariq, S., & Adeghate, E. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189824 · Cited by 6

Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis

Lv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6

GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis

Brady, S. M., Kane, M. P., & Busch, R. S. (2015) · AACE Clinical Case Reports · doi:10.4158/ep15658.cr · Cited by 7

Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells

Kim, M. J., Choi, O. K., Chae, K. S., Lee, H., Chung, S. S., Ham, D., Kim, J., Yoon, K., Park, K. S., & Jung, H. S. (2015) · Islets · doi:10.1080/19382014.2015.1129096 · Cited by 6

Analysis of long noncoding RNA-associated competing endogenous RNA network in glucagon-like peptide-1 receptor agonist-mediated protection in β cells

Cui, L., Bai, T., Zhi, L., Liu, Z., Liu, T., Xue, H., Yang, H., Yang, X., Zhang, M., Niu, Y., et al. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i9.374 · Cited by 6

Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists

Icart, L. P., de Souza, F. G., & Lima, L. M. T. R. (2021) · Journal of Microencapsulation · doi:10.1080/02652048.2021.1889059 · Cited by 6

The Impacts of Gastroileostomy Rat Model on Glucagon-like Peptide-1: a Promising Model to Control Type 2 Diabetes Mellitus

Keleidari, B., Mofrad, R. M., Shahmiri, S. S., Sanei, M. H., Kolahdouzan, M., & Sheikhbahaei, E. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3312-y · Cited by 6

SAD-A, a downstream mediator of GLP-1 signaling, promotes the phosphorylation of Bad S155 to regulate in vitro β-cell functions

Wang, K., Liu, D., Zhang, Y., Chang, X., Xu, R., Pang, J., Li, K., Sun, P. G., Zhu, Y., & Han, X. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.063 · Cited by 6

Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study

Elimihele, T. A., Mangrola, A. M., Oshomoji, O., Wilson, N., Nnamani, I., Ashong, B., Billings, S., Getu, D. K., Kumar, S., & Maliakkal, B. J. (2024) · Cureus · doi:10.7759/cureus.69152 · Cited by 5

The impact of glucagon-like peptide-1 receptor agonists on the quality indicators of colonoscopy – a systematic review and meta-analysis

Chiu, Y., Chen, Y., Lee, F., & Chang, C. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.03.004 · Cited by 5

Peptidylglycine monooxygenase activity of monomeric species of growth hormone

Donlon, J., & Ryan, P. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02436 · Cited by 5

The Future of Diabetes Therapies

Reinhart, J. M., & Graves, T. K. (2023) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.01.003 · Cited by 5

VPAC2 receptor mediates VIP-potentiated insulin secretion via ion channels in rat pancreatic β cells.

Zhao, X., Deng, L.-M., Ren, L., Yang, H., Wang, B., Zhu, X., Zhang, X.-L., Guo, C., Zhang, Y., & Liu, Y.-F. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113471 · Cited by 5

Strategies for glycemic control in nonobese and obese type 2 diabetic patients with coronary artery disease

Tsujimoto, T., & Kajio, H. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.008 · Cited by 5

Shared pathophysiology and therapeutic repurposing in Alzheimer's disease and type 2 diabetes: a critical review of convergent mechanisms and clinical challenges

Fu, W., Lu, R., Wang, D., & Sang, Z. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110044 · Cited by 4

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study

AlMuammar, S., & Alzahrani, H. (2025) · Saudi Medical Journal · doi:10.15537/smj.2025.46.8.20240100 · Cited by 4

Evidências cientificas sobre o uso de tirzepatida como tratamento da obesidade

Guimarães, B. C. D. S., Zanoteli, H. C., Chaves, R. P., Marcos, C. R. S. A., Aquino, M. E. F. V. D., Rosseto, J. S., Lopes, R. L., Lampert, A. R., & Peroba, G. G. P. D. A. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n4-137 · Cited by 9

Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico, in vitro, and in vivo analysis

Ahmed, F., Ahmad, S. S., Alam, M. M., Shaquiquzzaman, M., Altamish, M., Krishnan, A., Vohora, D., Najmi, A. K., & Khan, M. A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae112 · Cited by 4

Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population

Natale, F., Luisi, E., Franzese, R., Mollo, N., Solimene, A., Caso, V. M., Corvino, A., Golino, P., & Cimmino, G. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050145 · Cited by 5

A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1

Czech, T. Y., Wang, Q., & Seki, E. (2018) · Hepatology Communications · doi:10.1002/hep4.1147 · Cited by 4

An Exhaustive Exploration of the Semaglutide-GLP-1R Sequence Space towards the Design of Semaglutide Analogues with Elevated Binding Affinity to GLP-1RPreprint

Li, W. (2024) · Preprints.org · doi:10.20944/preprints202405.0258.v1 · Cited by 4

Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis

Wang, M., Wang, L., Sun, H., Yuan, H., & Li, Y. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05118-6 · Cited by 3

Can GLP-1RAs redefine transplantation standard of care?

Almalki, B. A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.013 · Cited by 4

EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice

Gao, H., Zhao, Q., Li, K., Qin, F., Yin, X., Lu, Z., Song, Z., Wu, Y., Shen, Y., Pan, Y., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112454 · Cited by 3

Phytochemical Screening, median lethal dose and effects of Cassia abbreviata Oliv. crude extracts and fractions on oral glucose tolerance in non-diabetic male Wistar rats

Musenge, E. M., Prashar, L., Ezeala, C. C., & Goma, F. M. (2024) · Medical Journal of Zambia · doi:10.55320/mjz.50.3.427 · Cited by 3

Pancreatic Glucagon-Like Peptide 1: What is known?

Fava, G. E. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000397 · Cited by 2

Bridging the Gap Between Diabetes and Stroke in Search of High Clinical Relevance Therapeutic Targets

Coppola, T., Béraud-Dufour, S., Lebrun, P., & Blondeau, N. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08563-5 · Cited by 5

Caulerpa okamuraeethanol extract improves the glucose metabolism and insulin sensitivityin vitroandin vivo

Park, C. M., Thakuri, L. S., & Rhyu, D. Y. (2021) · Journal of Applied Biological Chemistry · doi:10.3839/jabc.2021.014 · Cited by 3

Effects of long‐acting analogues of lamprey GLP‐1 and paddlefish glucagon on alpha‐ to beta‐cell transdifferentiation in an insulin‐deficient transgenic mouse model

Graham, G. V., Conlon, J. M., Moffett, R. C., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2021) · Journal of Peptide Science · doi:10.1002/psc.3328 · Cited by 3

The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity

Gilijamse, P. W., Demirkıran, A., van Wagensveld, B. A., Ackermans, M. T., Romijn, J. A., Nieuwdorp, M., ter Horst, K. W., & Serlie, M. J. M. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.04.022 · Cited by 4

A Case of Dulaglutide-Induced Vaginal Bleed

Vaccaro, C. J., Zaidi, S. M. H., Iskander, P. A., & McFadden, E. (2023) · Cureus · doi:10.7759/cureus.38774 · Cited by 3

IUPHAR review: Drug repurposing in Schizophrenia – An updated review of clinical trials

Zaki, J. K., Tomasik, J., & Bahn, S. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107633 · Cited by 3

Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients

Naciu, A. M., & Pozzilli, P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1441288 · Cited by 3

Oral Limonite Supplement Ameliorates Glucose Intolerance in Diabetic and Obese Mice

Uchida, A., Yasuma, T., Takeshita, A., Toda, M., Okano, Y., Nishihama, K., D’Alessandro‐Gabazza, C. N., D’Alessandro, V. F., Inoue, C., Takagi, T., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s320451 · Cited by 3

Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size

Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2

GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?

Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2

Incretin Therapy and Beta Cell Function

Goundan, P. N., UNDERWOOD, P. C., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.006 · Cited by 2

Preoperative Assessment of a Patient Undergoing Bariatric Surgery

Yuan, J. J., Bangalore, R., Darwish, D., Moon, T. S., & Wadhwa, A. N. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.07.005 · Cited by 4

Alpha cells as targets for incretin therapy

Lakhani, O. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_97_23 · Cited by 2

Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery

Li, J., Mohamed, B. A., Huang, S., & Peng, Y. G. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2494646 · Cited by 3

Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery

Connelly, J. W., Narayanan, R., Ezeonu, T., Kothari, P., Spina, N., Spiker, W. R., Lawrence, B. D., Brodke, D. S., Schroeder, G. D., & Karamian, B. A. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001888 · Cited by 2

Association between a glucagon-like peptide-1 receptor genetic polymorphism and therapeutic response to sitagliptin in type 2 diabetic patients: An observational study

Jawad, A. N., Kadhim, K. A., Ali, Z. H., Fawzi, H. A., & Alzajaji‏, Q. B. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01537-3 · Cited by 2

Selective beneficial cardiometabolic effects of vertical sleeve gastrectomy are predominantly mediated through glucagon-like peptide (GLP-1) in Zucker diabetic fatty rats

Kumar, S., Lau, R. G., Palaia, T. A., Hall, C. E., Lee, J., Hall, K. N., BRATHWAITE, C. E. M., & Ragolia, L. (2016) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2016.11.007 · Cited by 2

Role of glucagon-like peptide 1 (GLP-1) and its association with inflammatory markers in the pathogenesis of type 2 diabetes mellitus

Chawla, D., Kar, R., Puri, D., & Madhu, S. V. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.22.3.0094 · Cited by 2

Early protein restriction increases intra-islet GLP-1 production and pancreatic β-cell proliferation mediated by the β-catenin pathway

da Rosa-Santos, C. A., Rodrigues, P. D. C., Silva, L. R., Arantes, V. C., Reis, M. A. D. B., Colodel, É. M., Damazo, A. S., de Moura, E. G., Carneiro, E. M., & Latorraca, M. Q. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02192-6 · Cited by 2

Dipeptidyl Peptidase-4 (DPP4) Inhibitors

Pham, N.-Y. T., Argyropoulos, C., & Dinh, N. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_27 · Cited by 2

De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test

Pavlíková, B., Breburdova, M., Krčma, M., Kříž, M., Kasparek, J., & Rušavý, Z. (2024) · Life · doi:10.3390/life14050568 · Cited by 1

Structural and quantitative characterization of membrane N-glycans from MIN6 mouse pancreatic beta cells using liquid chromatography-quadrupole-Orbitrap tandem mass spectrometry

Jang, J. Y., Moon, C., Kim, K., Park, C. S., Jang, L., Jeong, C. M., Lee, H. S., Byeon, H., & Kim, H. H. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116494 · Cited by 1

Hypoglycemic Effect of Black Tea and Its Mechanism: Regulation of Glycometabolism and Intestinal Flora

Li, F., Zhou, H. J., Zhu, J., Wei, X., & Wang, Y. (2025) · Journal of Medicinal Food · doi:10.1089/jmf.2024.k.0251 · Cited by 1

Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis

Wang, D., Diao, H., Sun, W., Huan, W., Wang, Y., Ding, L., Cui, W., & Ma, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16585 · Cited by 1

Glucagon-like peptide-1 receptor agonists: prospects for use in the treatment of age-related diseases and aging

Bobok, N., & Halushko, O. A. (2025) · Problems of ageing and longevity (Ukraine) · doi:10.71012/pro-ageing-2025-4-05 · Cited by 1

Structural elucidation and antidiabetic activity of polysaccharides from the parasitic plant Orobanche cumana

Yang, S., Shen, H., Qiao, X., Song, Q., Tan, X., Li, X., Guo, P., Zhang, Y., Xiong, H., Wu, Y., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1785297 · Cited by 1

Alogliptin Attenuates Diclofenac‐Induced Acute Kidney Injury Associated With Activation of the AKT/Nrf2‐mediated Ferroptosis Pathway

Ghoneim, M. E.-S., Noureldin, M. H., Sayed, I. E., Banna, Y. Y. E., & Sayed, N. F. E. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70848 · Cited by 1

Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis

Tian, Y., Zheng, Z., Ma, Y., Ye, F., Pang, Y., Zhang, Z., Li, Z., Zhang, C., & Gao, J. (2026) · iScience · doi:10.1016/j.isci.2026.116347 · Cited by 1

Association of blood pressure and body weight decline during one-year treatment with the incretin analogue exenatide

Baretić, M., Renar, I. P., & Aganović, I. (2013) · Diabetologia Croatica · Cited by 1

Adiponectin, Diabetes, and the Cardiovascular System

Gasbarrino, K., Boutari, C., Filippaios, A., Gianopoulos, I., Daskalopoulou, S. S., & Mantzoros, C. S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_8 · Cited by 1

From a Glycocentric Approach to Prevention of Multi-Organ Damage in Type 2 Diabetes

Grover‐Páez, F., Gómez, A. M., Suárez, A., & Echauri, A. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002363 · Cited by 2

Cross-relationship between COVID-19 infection and anti-obesity products efficacy and incidence of side effects: A cross-sectional study

El-Mezayen, N. S., Abelrazik, Y. R., Khalifa, D. M., Dorbouk, N. M., Moaaz, M., Ali, M. M., Evy, A. G., Mohamed, E. G., Abdelhadi, A., Adly, I., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309323 · Cited by 1

Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions

Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1

Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients

Du, Q., Wang, Y., Yang, S., & Han, P. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s64691 · Cited by 1

В унісон із світовими тенденціями: клінічні аспекти застосування ліраглутиду в комбінації з інсуліном у пацієнтів із цукровим діабетом (огляд літератури і клінічні спостереження)

Zinych, О. В., Kushnariova, N. M., Ковальчук, А., Prybila, O. V., Shyshkan-Shyshova, К. О., Gurina, N. M., & Korpachev, V. V. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.7.79.2016.86417 · Cited by 1

Novel Antidiabetic Therapies and Cardiovascular Risk Reduction

Thompson, J., Schacht, S., & Rothenberg, F. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.04.007 · Cited by 1

Secreted PDZD2 exerts an insulinotropic effect on INS-1E cells by a PKA-dependent mechanism

So, D. H. ‐., Chan, J. C. Y., Tsui, M. G., Tsang, P. S. W., & Yao, K. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111026 · Cited by 1

Correlation between the antioxidant capacity of plasma and blood glucose level

Nurinda, E., Emelda, E., & Kusumawardani, N. (2021) · Pharmacy Education · doi:10.46542/pe.2021.212.108115 · Cited by 1

Effects of Combined Exercise on Insulin Resistance, Leptin, GLP-1 in Postmenopause Obesity Women

Kwak, D.-H., Koh, S.-H., Ha, S.-M., Kang, D.-W., & Kim, D. (2022) · 한국여성체육학회지 · doi:10.16915/jkapesgw.2022.9.36.3.207 · Cited by 1

The Role of the Equine Enteroinsular Axis in Insulin Dysregulation: In Vitro Mechanistic Insights for Disease Prevention

Kheder, M. H. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122879 · Cited by 1

Can Semaglutide Bind Tighter to GLP-1R?Preprint

Li, W. (2020) · Preprints.org · doi:10.20944/preprints202007.0582.v1

Assessment of β-Cell Function

Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_2

The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review protocol

Bellman, S. M., & Aromataris, E. (2014) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2014-1858 · Cited by 1

Diabetes Mellitus in Cats Relevant to Human Type 2 Diabetes – Current Knowledge and New Treatment Strategies – A Review

Palus, K., & Całka, J. (2014) · Annals of Animal Science · doi:10.2478/aoas-2014-0067

The History of GLP-1 and the Debate Regarding Its Tissue-Specific Expression

Fava, G. E., & Wu, H. (2014)

Impacto do balão intragástrico associado à dieta no tratamento do paciente diabético com sobrepeso ou obesidade grau I e sua influência na produção de enterohormônios

Reimão, S. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-14032018-122506

A Rare Cause of Delayed Puberty in Two Siblings: A Case Report

Kocaay, P. (2020) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.99284

Glucagon-Like Peptide-1 Receptor Agonist Effects on Gastric Motility: A Systematic Review

Wongjarupong, N., Al-Hameed, M., Suchartikitwong, S., Assavapongpaiboon, B., & Salehian, B. (2020) · Diabetes & its Complications · doi:10.33425/2639-9326.1076

Novel mouse model expands potential human α-cell research

dos Santos, T., & MacDonald, P. E. (2021) · Islets · doi:10.1080/19382014.2021.1914507

Oral GLP-1 Analogue Ameliorates Obesity-Induced Diabetes In Db/Db MousePreprint

Zhang, H., Dong, M., & Jin, W. (2021) · Research Square · doi:10.21203/rs.3.rs-812353/v1

Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"

(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review2

Decision letter for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"

(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/decision1

Decision letter for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"

(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/decision1

Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"

(2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v1/review3

Author response for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"

Reifsnider, O. S., Pimple, P. M., Brand, S. B., Washington, E. B., Shetty, S. S., & Desai, N. R. (2021) · Publons reviews and discussion · doi:10.1111/dom.14625/v2/response1

Antidiabetic Agents

LeRoy, J. M., & Stellpflug, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-20790-2_112-1

Antidiabetic Agents

LeRoy, J. M., & Stellpflug, S. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_112

Liraglutide dans le traitement de l’obésité : une prise en charge multidisciplinaire

Nest, S., Gilet, P., Vetta, V. D., Dudin, F., Frantz, J., & Favre, L. (2022) · JMIG · doi:10.53738/revmed.2022.18.774.516

The Effect of Cigarette Smoke Exposure with Bidara (Sidr) Leaf Powder Biofilter on Glucose Levels and Pancreas Histology in Mice Diabetes Mellitus

Mulyono, A. (2022) · International Journal of Design & Nature and Ecodynamics · doi:10.18280/ijdne.170209

Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico

Costanzo, G., & Frasca, F. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01064-x

Probiotics for immune disease prevention and treatment

Pelúzio, M. D. C. G., Rosa, C. D. O. B., Pereira, M. D. F. A., Dias, M. D. M. E., Bernardes, A. L., Cruz, B. C. D. S., Milagro, F. I., & Bressan, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89908-6.00004-2

Fast Skeletal Muscle Troponin and Tropomyosin as a Dietary Source of Antidiabetic and Antihypertensive Bioactive Peptides: An In Silico Study

Barrero, J. A., Barrero, M. A., Clavijo, A. ́. G., & Cruz, C. M. (2023) · Revista Vitae · doi:10.17533/udea.vitae.v30n1a347310 · Cited by 1

Role of selenium and selenoprotein in animal liver health

Hui, Z. H. O. U., YiWen, H. E., Yin, Y., TieJun, L. I., & He, L. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0107

Weight loss medications: A new Pandora’s box?

Mohan, B. P. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.05.018

Commentary—Fasting Implications of GLP-1 Agonist Use in Pediatric Procedural Sedation

Sullivan, M. D., & Thikkurissy, S. (2025) · Anesthesia Progress · doi:10.2344/24-0034

Retatrutide: A novel approach in the treatment of obesity, diabetes mellitus, and MASLD (metabolic dysfunction-associated steatotic liver disease)

Prosecký, R., & Karoliová, K. H. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.041

Glucagon‐like peptide 1‐potentiated insulin secretion and proliferation of pancreatic β‐cells GLP‐1促进胰岛素分泌和胰岛β细胞增殖的机制

Ma, X., Guan, Y., & Hua, X. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12161 · Cited by 35

Effect of glucagon-like peptide-1 on pancreatic β-cells

An, R. (2009) · International Journal of Pathology and Clinical Medicine

Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death

Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells

Xiong, X., Shao, W., & Jin, T. (2012) · Islets · doi:10.4161/isl.23345 · Cited by 27

Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells

Caporarello, N., Parrino, C., Trischitta, V., & Frittitta, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181190 · Cited by 12